Avricore Health Announces Return of HealthTab Founder to Communications and Marketing Role Medical Device Investing
Solarvest Bioenergy Inc. Announces Increase in Offering Size of Non-Brokered Private Placement to Existing Shareholders and Other Investors Biotech Investing
European Medicines Agency Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer Biotech Investing
Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain Pharmaceutical Investing
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Biotech Investing
Notice of Lead Plaintiff Deadline for Shareholders in the BELLUS Health Inc. Class Action Lawsuit Biotech Investing
Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival Biotech Investing
Real-World Evidence Supports Effectiveness of First-line IBRANCE® Combination Therapy in HR+, HER2- Metastatic Breast Cancer Pharmaceutical Investing
ALERT FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Biotech Investing
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the Firm Biotech Investing
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BELLUS Health Inc. Biotech Investing
